InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
0.8070
-0.0081 (-0.99%)
At close: Aug 8, 2025, 4:00 PM
0.8165
+0.0095 (1.18%)
After-hours: Aug 8, 2025, 7:53 PM EDT
InflaRx Employees
InflaRx had 74 employees as of December 31, 2024. The number of employees increased by 12 or 18.97% compared to the previous year.
Employees
74
Change (1Y)
12
Growth (1Y)
18.97%
Revenue / Employee
$2,584
Profits / Employee
-$718,791
Market Cap
54.67M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 74 | 12 | 18.97% |
Dec 31, 2023 | 62 | 18 | 40.41% |
Dec 31, 2022 | 44 | -12 | -20.75% |
Dec 31, 2021 | 56 | 9 | 18.18% |
Dec 31, 2020 | 47 | 4 | 8.24% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
IFRX News
- 1 day ago - InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 8 days ago - InflaRx to Report Second Quarter 2025 Results on August 7, 2025 - GlobeNewsWire
- 4 weeks ago - InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewsWire
- 2 months ago - InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease - Benzinga
- 2 months ago - InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum - GlobeNewsWire
- 2 months ago - InflaRx to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - InflaRx to Report First Quarter 2025 Results on May 7, 2025 - GlobeNewsWire